Pricing Log in Create free account

Lexeo Therapeutics, Inc. (LXEO) vs SAB Biotherapeutics, Inc. (SABS)

Lexeo Therapeutics, Inc. and SAB Biotherapeutics, Inc. are both Biotechnology companies. Lexeo Therapeutics, Inc. and SAB Biotherapeutics, Inc. are of similar size ($235.7M and $226.6M). Across the 12 metrics below, SAB Biotherapeutics, Inc. leads on 8 and Lexeo Therapeutics, Inc. on 4.

Valuation

Metric LXEO SABS Biotechnology median
P/E n/m n/m 8.50
P/S n/m 123.99 9.71
P/B 0.96 0.94 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales n/m 62.79 9.21
Earnings yield (43.56%) (25.30%) (33.15%)
Free cash flow yield (39.24%) (28.47%) (25.50%)

Profitability

Metric LXEO SABS Biotechnology median
Gross margin 0.00% 100.00% 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (46.76%) (19.21%) (56.36%)
Return on assets (40.50%) (16.24%) (48.04%)
Return on invested capital (253.48%) (38.97%) 0.00%

Growth

Metric LXEO SABS Biotechnology median
Revenue growth (TTM) — (60.26%) 6.02%
EPS growth (last fiscal year) 39.81% 78.53% 30.26%
Revenue growth, 5-year CAGR — — 9.41%
Net income growth, 5-year CAGR 0.00% (26.69%) 0.00%

Health

Metric LXEO SABS Biotechnology median
Debt to equity 0.00 0.01 0.00
Current ratio 13.89 9.22 4.72
Net debt to EBITDA 1.67 2.03 0.96

Dividend

Metric LXEO SABS Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric LXEO SABS Biotechnology median
Market cap 226.56m 235.66m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack